Daratumumab (Darzalex▼): risk of reactivation of hepatitis B virus

Source:
GOV UK
Publisher:
Medicines and Healthcare products Regulatory Agency
Publication date:
19 August 2019

Abstract

Establish hepatitis B virus status before initiating daratumumab and in patients with unknown hepatitis B virus serology who are already being treated with daratumumab.